Objective To compare the influence of radiotherapy,chemotherapy and radiation combined with chemotherapy in the treatment of patients with non-small cell lung cancer on the state of EGFR gene mutation.Methods 328 patients with non-small cell lung cancer were selected.On the basis of the condition of the patients,they were treated with radiation therapy,combination treatment with chemotherapy and radiation.And according to the different treatment methods,they were divided into chemotherapy group (112 cases),radiotherapy group (108 cases) and radiation combined with chemotherapy group(108 cases).Before and after treatment,the plasma EGFR mutations situation was detected and analyzed.Results Before treatment,the plasma EGFR mutation rates in the chemotherapy,radiotherapy,radiation combined with chemotherapy group were 34.82％ (39/112),31.48％ (34/108),32.41％ (35/108),which were significantly higher than 20.54％ (23/112),18.52％ (20/108),19.44％ (21/108) after treatment(x2 =5.709,4.840,4.725,all P ＜ 0.05).The frequency of the mutant EGFR gene in the patients after chemotherapy was 20.5％ (23/112),which was significantly lower than 34.8％ (39/112) before chemotherapy,the difference was statistically significant(x2 =5.709,P ＜ 0.05).After radiotherapy,the frequency of the mutant EGFR gene in the patients was 18.5 ％ (20/108),which was significantly lower than 31.5 ％ (34/108) before radiotherapy,the difference was statistically significant(x2 =4.840,P ＜ 0.05).After chemoradiation therapy,the frequency of the mutant EGFR gene in the patients was 19.4％ (21/108),which was significantly lower than 32.4％ (35/108) before chemoradiation therapy,the difference was statistically significant (x2 =4.725,P ＜ 0.05).Conclusion Radiotherapy,chemotherapy and radiation combined with chemotherapy in the treatment of non-small cell lung cancer can affect the state of EGFR gene mutation,which has significant decline.

Objective To investigate the clinical effect and patients of docetaxel and cisplatin combined with radiotherapy for advanced esophageal carcinoma of the safety and the effect on the immune status of patients. Methods 104 cases of advanced esophageal cancer patients admitted in Dongyang People's Hospital from January 2011 to June 2014 were divided into the control group and the observation group with 52 cases in each group. The two groups of patients were treated with three-dimensional conformal radiotherapy, total dose of 55~65gy, the course of treatment was six weeks, at the same time, the control group were treated with cisplatin (20mg/m2) combined with 5-fluorouracil (400mg/m2) chemotherapy, the observation group were treated with cisplatin (20mg/m2) combined with docetaxel (120mg/m2) chemotherapy, the course of treatment was three weeks. Compared the two groups of patients with clinical treatment effect, survival rate and the average survival time, adverse reaction rate, and detection of two groups of patients before and after the treatment of immune function index CD3+, CD4+, CD8+ and CD4+/CD8+ levels. Results The total effective rate of observation group was 86.53%, the total effective rate of control group was 69.23%, the difference was statistically significant (P< 0.05), the patients in the observation group two years survival rate and mean survival time were significantly better than the control group, the difference was statistically significant (P< 0.05), the adverse reaction rate of the observation group was 59.62%, the adverse reaction rate of the control group was 65.38%, the difference was statistically significant (P< 0.05), two patients immune function indexes of CD3+, CD4+, CD8+ and CD4+/CD8+ levels had no significant difference before treatment after treatment, patients in the observation group, CD4+, CD3+, CD8+and CD4+/CD8+were significantly better than the control group, the difference was statistically significant (P< 0.05). Conclusion Three-dimensional conformal radiotherapy based on cisplatin combined with docetaxel chemotherapy is superior to cisplatin combined with 5-fluorouracil chemotherapy, and less adverse reaction, while patients with advanced esophageal carcinoma immune function less.